Posted on

cbd oil trials australia

Study site: Woolcock Institute of Medical Research, Glebe, NSW 2037

Exploring the effects of combined CBD and THC (20:1) on sleep and brain activation in patients with insomnia disorder. Eligible participants undergo two overnight sleep studies receiving randomised active and placebo treatments. This study is being led by Professor Ron Grunstein. See here for more information.

Exploring the effect of combined THC and CBD (1:1) on tics in patients with Tourette syndrome. Eligible participants will undergo two 8-week treatment periods receiving either active or placebo treatment. This study is being led by Dr Philip Mosley. See here for more information.

Tourette Syndrome

Access resources on medicinal cannabinoids produced by ACRE including the NSW Cannabis Medicines Prescribing Guidance to provide interim information to support NSW medical practitioners in prescribing cannabis medicines.

ACRE research team shares combined experience that includes public health care, pharmacovigilance, clinical pharmacology and drug development, clinical and basic human/animal research skills, environmental and translational research.

is working to develop a national research and policy framework that ensures quality and safety in the implementation of medicinal cannabis use in the community.


The Australian Centre

The Australian Centre for Cannabinoid Clinical and Research Excellence is a National Health and Medical Research Council Centre of Research Excellence.

ACRE’s multi-disciplinary research is gathering the information necessary to inform best clinical practice and to guide government around the use of medicinal cannabinoids in Australia

Access book chapters, journal articles, editorials and commentaries, and reports contributed to and produced by ACRE investigators and members

Cannabinoids for Symptom Control in Advanced Cancer, an Open Label Prospective Clinical Trial in NSW.

Patients with advanced cancer who experience uncontrolled symptoms of pain and/or nausea and/or anorexia as well as meet the inclusion criteria are invited to participate.

Participants will be prescribed these oils at no cost until they withdraw from the study or are no longer able to take them. Treatment will be given in addition to the participant’s usual medical treatments for advanced cancer and symptom control. Prior or current use of medicinal cannabis is not an exclusion to participate.

All participants will be prescribed a cannabis medicine from a range of oral oils registered for human use in Australia. The cannabis medicines will be either predominantly Delta-9-Tetrahydrocannabinol (THC) or a combination of THC and Cannabidiol (CBD) in near equal amounts.

CARE NSW will recruit up to 600 participants over three years and is expected to involve at least 10 hospitals from across the state.